Treatment of venous thrombosis with an oral direct factor Xa inhibitor edoxaban by single and multiple administrations in rats

European Journal of Pharmacology

Volumn 742, Issue , 2014, Pages 15-21

  Morishima, Yoshiyuki ^a   Kamisato, Chikako ^a   Honda, Yuko ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Animal models; Edoxaban; Factor; Oral anticoagulant; Treatment effect; Venous thrombosis; Xa inhibitor

Indexed keywords

EDOXABAN; ENOXAPARIN; FONDAPARINUX; ANTICOAGULANT AGENT; ANTITHROMBIN III; ANTITHROMBIN III-PROTEASE COMPLEX; BLOOD CLOTTING FACTOR 10A INHIBITOR; PEPTIDE HYDROLASE; POLYSACCHARIDE; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; BLOOD CLOTTING; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; MALE; NONHUMAN; RAT; SINGLE DRUG DOSE; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; ANIMAL; BLOOD; COMPARATIVE STUDY; DISEASE MODEL; DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PATHOLOGY; VENOUS THROMBOSIS; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; ANTITHROMBIN III; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; ENOXAPARIN; FACTOR XA INHIBITORS; MALE; PEPTIDE HYDROLASES; POLYSACCHARIDES; PYRIDINES; RATS; RATS, WISTAR; THIAZOLES; VENOUS THROMBOSIS;

EID: 84908063333     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.08.020     Document Type: Article

References (22)

1. G. Agnelli, H.R. Buller, A. Cohen, M. Curto, A.S. Gallus, M. Johnson, U. Masiukiewicz, R. Pak, J. Thompson, G.E. Raskob, and J.I. Weitz AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism N. Engl. J. Med. 369 2013 799 808
2. B.J. Biemond, E. Perzborn, P.W. Friederich, M. Levi, U. Buetehorn, and H.R. Büller Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939) -an oral, direct factor Xa inhibitor Thromb. Haemost. 97 2007 471 477
3. D.P. Brandjes, H. Heijboer, H.R. Büller, M. de Rijk, H. Jagt, and J.W. ten Cate Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis N. Engl. J. Med. 327 1992 1485 1489
4. S Carlsson, M. Elg, and C. Mattsson Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats Thromb. Res. 107 2002 163 168
5. S.B. Deitelzweig, J. Lin, C. Kreilick, M. Hussein, and D. Battleman Warfarin therapy in patients with venous thromboembolism: patterns of use and predictors of clinical outcomes Adv. Ther. 27 2010 623 633
6. EINSTEIN Investigators R. Bauersachs, S.D. Berkowitz, B. Brenner, H.R. Buller, H. Decousus, A.S. Gallus, A.W. Lensing, F. Misselwitz, M.H. Prins, G.E. Raskob, A. Segers, P. Verhamme, P. Wells, G. Agnelli, H. Bounameaux, A. Cohen, B.L. Davidson, F. Piovella, and S. Schellong Oral rivaroxaban for symptomatic venous thromboembolism N. Engl. J. Med. 363 2010 2499 2510
7. EINSTEIN-PE Investigators H.R. Büller, M.H. Prins, A.W. Lensin, H. Decousus, B.F. Jacobson, E. Minar, J. Chlumsky, P. Verhamme, P. Wells, G. Agnelli, A. Cohen, S.D. Berkowitz, H. Bounameaux, B.L. Davidson, F. Misselwitz, A.S. Gallus, G.E. Raskob, S. Schellong, and A. Segers Oral rivaroxaban for the treatment of symptomatic pulmonary embolism N. Engl. J. Med. 366 2012 1287 1297
8. T. Fuji, S. Fujita, S. Tachibana, Y. Kawai, Y. Koretsune, T. Yamashita, and M. Nakamura Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V trial Blood (ASH Annu. Meet. Abstr.) 116 2010 3320
9. T. Fuji, S. Fujita, S. Tachibana, and Y. Kawai Edoxaban versus enoxaparin for the prevention of venous thromboembolism pooled analysis of venous thromboembolism and bleeding from STARS E-3 and STARS J-V Blood (ASH Annu. Meet. Abstr.) 118 2011 208
10. S. Fujita, T. Fuji, S. Tachibana, M. Nakamura, and M. Kawai Safety and efficacy of edoxaban in patients undergoing hip fracture surgery Pathophysiol. Haemost. Thromb. 37 A95 2010 P366
11. T. Fukuda, N. Tsuji, Y. Honda, C. Kamisato, Y. Morishima, and T. Shibano Comparison of antithrombotic efficacy between edoxaban, a direct factor Xa inhibitor, and fondaparinux, an indirect factor Xa inhibitor under low and high shear rates Thromb. Haemost. 106 2011 1062 1068
12. T. Furugohri, K. Isobe, Y. Honda, C. Kamisato-Matsumoto, N. Sugiyama, T. Nagahara, Y. Morishima, and T. Shibano DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles J. Thromb. Haemost. 6 2008 1542 1549
13. T. Furugohri, T. Fukuda, N. Tsuji, A. Kita, Y. Morishima, and T. Shibano Melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, nor heparin aggravates tissue factor-induced hypercoagulation in rats Eur. J. Pharmacol. 686 2012 74 80
14. Hokusai-VTE Investigators H.R. Büller, H. Décousus, M.A. Grosso, M. Mercuri, S. Middeldorp, M.H. Prins, G.E. Raskob, S.M. Schellong, L. Schwocho, A. Segers, M. Shi, P. Verhamme, and P. Wells Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism N. Engl. J. Med. 369 2013 1406 1415
15. C. Kearon A conceptual framework for two phases of anticoagulant treatment of venous thromboembolism J. Thromb. Haemost. 10 2012 507 511
16. C. Kearon, E.A. Akl, A.J. Comerota, P. Prandoni, H. Bounameaux, S.Z. Goldhaber, M.E. Nelson, P.S. Wells, M.K. Gould, F. Dentali, M. Crowther, S.R. Kahn American College of Chest Physicians Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines Chest 141 Suppl 2 2012 e419S e494S
17. R.J. Leadley Jr Coagulation factor Xa inhibition: biological background and rationale Curr. Top. Med. Chem. 1 2 2001 151 159
18. Y. Morishima, K. Tanabe, Y. Terada, T. Hara, and S. Kunitada Antithrombotic and haemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants Thromb. Haemost. 78 1997 1366 1371
19. Y. Morishima, Y. Honda, C. Kamisato, N. Tsuji, A. Kita, N. Edo, and T. Shibano Comparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in rats Thromb. Res. 130 2012 514 519
20. Y. Morishima, Y. Honda, C. Kamisato, and T. Shibano Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats Thromb. Res. 132 2013 234 239
21. K. Ogata, J. Mendell-Harary, M. Tachibana, H. Masumoto, T. Oguma, M. Kojima, and S. Kunitada Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers J. Clin. Pharmacol. 50 2010 743 753
22. S. Schulman, C. Kearon, A.K. Kakkar, P. Mismetti, S. Schellong, H. Eriksson, D. Baanstra, J. Schnee, S.Z. Goldhaber RE-COVER Study Group Dabigatran versus warfarin in the treatment of acute venous thromboembolism N. Engl. J. Med. 361 2009 2342 2352